COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,284 Articles (22,759 medRxiv, 8,525 bioRxiv)

Most recent first Previous |  Page 596: Articles 5951-5960  | Next

Scoping review and meta-analysis of COVID-19 epidemiological parameters for modeling from early Asian studies
Fonfria, E. S., Vigo, M. I., Garcia-Garcia, D., Herrador, Z., Navarro, M., BORDEHORE, C.
10.1101/2022.10.23.22281408 — Posted: 2022-10-25
NC-COVID: A Time-Varying Compartmental Model for Estimating SARS-CoV-2 Infection Dynamics in North Carolina, US
Delamater, P. L., Woodul, R. L.
10.1101/2022.10.21.22281271 — Posted: 2022-10-25
COVID-19 vaccine equity and the right to health for displaced Venezuelans in Latin America
Hill, D., Andrade-Romo, Z., Solari, K., Adams, E., Forman, L., Grace, D., Silva-Santisteban, A., Perez-Brumer, A.
10.1101/2022.10.21.22281363 — Posted: 2022-10-25
Comparative Effectiveness of Dexamethasone in Treatment of Hospitalized COVID-19 Patients during the First Year of the Pandemic: The N3C Data Repository
Zhou, R., Johnson, K. E., Rousseau, J. F., Rathouz, P. J., The N3C Consortium
10.1101/2022.10.22.22281373 — Posted: 2022-10-24
Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
Desautels, T. A., Arrildt, K. T., Zemla, A. T., Lau, E. Y., Zhu, F., Ricci, D., Cronin, S., Zost, S., Binshtein, E., Scheaffer, S. M., Engdahl, T. B., Chen, E., Goforth, J. W., Vashchenko, D., Nguyen, S., Weilhammer, D. R., Lo, J. K.-Y., Rubinfeld, B., Saada, E. A., Weisenberger, T., Lee, T.-H., Whitener, B., Case, J. B., Ladd, A., Silva, M. S., Haluska, R. M., Grzesiak, E. A., Bates, T. W., Petersen, B. K., Thackray, L. B., Segelke, B. W., Lillo, A. M., Sundaram, S., Diamond, M. S., Crowe, J. E., Carnahan, R. H., Faissol, D. M.
10.1101/2022.10.21.513237 — Posted: 2022-10-24
The ACE-2 receptor accelerates but is not biochemically required for SARS-CoV-2 membrane fusion.
Cervantes, M., Hess, T., Morbioli, G. G., Sengar, A., Kasson, P. M.
10.1101/2022.10.22.513347 — Posted: 2022-10-24
Phenotypic alteration of low-density granulocytes in people with pulmonary post-acute sequalae of SARS-CoV-2 infection
Dean, L. S., Devendra, G., Jiyarom, B., Subia, N., Tallquist, M. V., Nerurkar, V. R., Chang, S. P., Chow, D. C., Shikuma, C. M., Park, J.
10.1101/2022.10.22.513351 — Posted: 2022-10-24
Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape
Burn Aschner, C., Muthuraman, K., Kucharska, I., Cui, H., Prieto, K., Nair, M. S., Wang, M., Huang, Y., Christie-Holmes, N., Poon, B., Lam, J., Sultana, A., Kozak, R., Mubareka, S., Rubinstein, J. L., Rujas, E., Treanor, B., Ho, D. D., Jetha, A., Julien, J.-P.
10.1101/2022.10.23.513379 — Posted: 2022-10-24
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
Patel, A., Kumar, S., Lai, L., Chakravarthy, C., Valanparambil, R., Reddy, E. S., Gottimukkala, K., Bajpai, P., Raju, D. R., Edara, V. V., Davis-Gardner, M. E., Linderman, S., Dixit, K., Sharma, P., Mantus, G., Cheedarla, N., Verkerke, H. P., Frank, F., Neish, A. S., Roback, J. D., Davis, C. W., Wrammert, J., Ahmed, R., Suthar, M., Sharma, A., Murali-Krishna, K., Chandele, A., Ortlund, E. A.
10.1101/2022.10.24.513517 — Posted: 2022-10-24
Vaccine- and BTI-elicited pre-Omicron immunity more effectively neutralizes Omicron sublineages BA.1, BA.2, BA.4 and BA.5 than pre-Omicron infection alone
Santos da Silva, E., Servais, J.-Y., Kohnen, M., Arendt, V., Gilson, G., Staub, T., Seguin-Devaux, C., Perez-Bercoff, D.
10.1101/2022.10.24.513415 — Posted: 2022-10-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).